This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Nov. 23, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced that it will host a conference call to discuss the approval of Intermezzo® (zolpidem tartrate sublingual tablet) by the U.S. Food and Drug Administration.
Conference Call InformationDate:
Wednesday, November 23, 2011Time:
2:30 p.m. ETDial-in (U.S.): 877-638-4558Dial-in (International): 914-495-8537
A simultaneous web cast of the conference call will be available on the Investors section of the Transcept website at
www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until
December 31, 2011.
A telephone replay of the conference call will be available shortly after the conclusion of the call until end of business
November 30, 2011. The replay telephone numbers are 855-859-2056 (U.S.) and 404-537-3406 (International), replay passcode: 30305793.
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo (zolpidem tartrate sublingual tablet) is the first FDA approved Transcept product and is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Transcept and
Purdue have entered into a collaboration agreement for the development and commercialization of Intermezzo in
the United States.
Transcept is currently conducting a Phase 2 study of TO-2061, a low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with approved first-line pharmacotherapy. For further information, please visit the Transcept website at: